EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc., a clinical-stage drug discovery company developing corrector therapies for protein misfolding diseases, today announced that the first patient has been dosed in its ongoing Phase 1/2 clinical study evaluating OCT-980, an investigational oral small molecule for the treatment of rhodopsin-associated autosomal dominant Retinitis Pigmentosa (RHO-adRP). RHO-adRP is an inherited retinal disease caused by mutations in the RHO gene, the most common for